Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States

Sample attrition. aDue to exclusion of patients with capitated claims for the cost analysis, 149 patients of the 209 treated HR-MDS patients were available for cost of care analyses. 1LT first-line therapy, AML acute myeloid leukemia, HR-MDS higher-risk myelodysplastic syndrome, MDS myelodysplastic syndrome, SCT stem cell transplan